VTYX News and Press, Ventyx Biosciences Inc. From 05/05/22

ENCINITAS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, toda...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

The following slide deck was published by Ventyx Biosciences, Inc. in conjunction with this event. For further details see: Ventyx Biosciences (VTYX) Investor Presentation - Slideshow

Ventyx Biosciences press release (NASDAQ:VTYX): FY GAAP EPS of -$6.65 beats by $0.87. Cash, cash equivalents and marketable securities were $286.7 million as of December 31, 2021. For further details see: Ventyx Biosciences GAAP EPS of -$6.65 beats by $0.87

Topline Phase 1 data for our allosteric TYK2 inhibitor, VTX958, expected in early Q3 2022 Topline Phase 1 data for our oral, selective NLRP3 inhibitor, VTX2735, expected in Q2 2022 Phase 2 trial of our S1P1R modulator, VTX002, continues to enroll in ulcerative colitis (U...

ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and...

Dan Loeb's 13F portfolio value decreased from $18.32B to $14.33B this quarter. The number of positions decreased from 113 to 92. Third Point increased Amazon, RH, and Catalent while decreasing Upstart Holdings and Walt Disney during the quarter. The top three positions are at ~23%...

ENCINITAS, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and ...

ENCINITAS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and...

Ventyx Biosciences (NASDAQ:VTYX): Q3 Net Loss of $12.8M Cash, cash equivalents and marketable securities of $142M Press Release For further details see: Ventyx Biosciences reports Q3 results